Q1 EPS Estimate for Edgewise Therapeutics Reduced by Analyst

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Equities research analysts at Wedbush reduced their Q1 2025 earnings per share estimates for shares of Edgewise Therapeutics in a report issued on Wednesday, April 2nd. Wedbush analyst L. Chico now expects that the company will post earnings of ($0.40) per share for the quarter, down from their prior estimate of ($0.36). The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($1.45) per share. Wedbush also issued estimates for Edgewise Therapeutics’ FY2025 earnings at ($1.69) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.58) EPS, Q4 2026 earnings at ($0.60) EPS and FY2027 earnings at ($1.81) EPS.

A number of other analysts have also weighed in on EWTX. Evercore ISI increased their price objective on shares of Edgewise Therapeutics from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 17th. Stifel Nicolaus assumed coverage on Edgewise Therapeutics in a research note on Wednesday, January 22nd. They issued a “hold” rating and a $30.00 target price on the stock. Scotiabank cut shares of Edgewise Therapeutics from a “sector outperform” rating to a “sector perform” rating and cut their price target for the stock from $50.00 to $14.00 in a report on Wednesday, April 2nd. Royal Bank of Canada lowered their price objective on shares of Edgewise Therapeutics from $56.00 to $52.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $51.00 target price on shares of Edgewise Therapeutics in a research report on Wednesday, April 2nd. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Edgewise Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $40.38.

Edgewise Therapeutics Trading Down 15.2 %

Edgewise Therapeutics stock opened at $11.51 on Monday. Edgewise Therapeutics has a 12-month low of $11.50 and a 12-month high of $38.12. The firm has a 50-day moving average price of $25.20 and a 200-day moving average price of $28.54. The firm has a market capitalization of $1.21 billion, a PE ratio of -7.67 and a beta of 0.32.

Edgewise Therapeutics (NASDAQ:EWTX) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.03).

Insider Activity

In other news, Director Orbimed Advisors Llc bought 496,771 shares of the firm’s stock in a transaction that occurred on Thursday, April 3rd. The stock was bought at an average price of $20.13 per share, with a total value of $10,000,000.23. Following the completion of the transaction, the director now directly owns 14,809,075 shares of the company’s stock, valued at approximately $298,106,679.75. The trade was a 3.47 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Joanne M. Donovan sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $27.63, for a total transaction of $690,750.00. Following the completion of the sale, the chief marketing officer now owns 16,358 shares of the company’s stock, valued at approximately $451,971.54. This trade represents a 60.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 34,836 shares of company stock worth $986,245. Corporate insiders own 24.11% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Paradigm Biocapital Advisors LP boosted its holdings in Edgewise Therapeutics by 61.1% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,493,929 shares of the company’s stock worth $119,988,000 after acquiring an additional 1,704,757 shares in the last quarter. First Light Asset Management LLC purchased a new position in shares of Edgewise Therapeutics in the 4th quarter valued at approximately $20,843,000. Foresite Capital Management VI LLC acquired a new stake in Edgewise Therapeutics in the 4th quarter worth approximately $15,620,000. Janus Henderson Group PLC grew its position in Edgewise Therapeutics by 9.3% during the 4th quarter. Janus Henderson Group PLC now owns 4,983,940 shares of the company’s stock worth $133,044,000 after purchasing an additional 425,421 shares during the last quarter. Finally, Braidwell LP increased its stake in Edgewise Therapeutics by 19.1% during the 4th quarter. Braidwell LP now owns 2,332,196 shares of the company’s stock valued at $62,270,000 after purchasing an additional 373,886 shares in the last quarter.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.